Publication Year

Alavian KN, Dworetzky SI, Bonanni L, Zhang P, Sacchetti S, Mariggio MA, Onofrj M, Thomas A, Li H, Mangold JE, Signore AP, Demarco U, Demady DR, Nabili P, Lazrove E, Smith PJS, Gribkoff VK, Jonas EA. 2012. Effects of dexpramipexole on brain mitochondrial conductances and cellular bioenergetic efficiency. Brain Res 1446:1–11.

Kirman, CR, Hays, SM, Aylward, LL, Suh, M, Harris, MA, Thompson, CM, Haws, LC, Proctor, DM. 2012. Physiologically based pharmacokinetic model for rats and mice orally exposed to chromium. Chem Biol Interact 200(1):45-64.

Brorby G, Proctor D, Perry C, Fitzgerald L, Tachovsky A. 2012. Probabilistic risk assessment of human exposure to iron and steel slag. Presented at the Society of Toxicology’s 51st Annual Meeting, March 11-15, San Francisco, CA.

Doepker CL, Maier A, Willis A, Hermansky S. 2012. Toxicology of flavors in the food industry. Chapter 7 In: Bingham E, Cohrssen B., eds. Patty’s Toxicology, Sixth ed. New York: Wiley & Sons.

Kopec AK, Thompson CM, Kim S, Forgacs AL, Zacharewski TR. 2012. Comparative toxicogenomic analysis of oral Cr(VI) exposure effects in rat and mouse small intestinal epithelium. Toxicol Appl Pharmacol 262(2):124-138.

Finch G, Mounho B. 2012. Development of biosimilar products: Overview of standards and regulations. Presented at the Society of Toxicology’s 51st Annual Meeting, March 11-15, San Francisco, CA.

Katyal A, Petrisor IG. 2012. Innovative sustainable drought management strategy incorporating forensic techniques and policy framework. Environ Foren 13(2):122–139.

Wikoff DW, Fitzgerald L, Birnbaum L. 2012. Persistent organic pollutants: An overview. In: Schecter, A. (ed.), Dioxins and Health Including Other Persistent Organic Pollutants and Endocrine Disruptors, 3rd edition. John Wiley & Sons, Inc., pp. 1-35.

Kopec AK, Kim S, Forgacs AL, Zacharewski TR, Proctor DM, Harris MA, Haws LC, Thompson CM. 2012. Genome-wide gene expression effects in B6C3F1 mouse intestinal epithelia following 7 and 90 days of exposure to hexavalent chromium in drinking water. Toxicol Appl Pharmacol 259(1):13-26.

Harris MA, Thompson CM, Wolf JC, Fedorov Y, Hixon JG, Proctor DM, Suh M, Haws LC. 2012. Assessment of genotoxic potential of Cr(VI) in the intestine via in vivo intestinal micronucleus assay and in vitro high content analysis in differentiated and undifferentiated caco-2. Presented at the Society of Toxicology’s 51st Annual Meeting, March 11-15, San Francisco, CA.

Proctor DM, Suh M, Aylward LL, Kirman CR, Harris MA, Thompson CM, Gürleyük H, Gerads R, Haws LC, Hays SM. 2012. Hexavalent chromium reduction kinetics in rodent stomach contents. Chemosphere 89(5): 487-493.

Haws L, Fitzgerald L, Burkhalter K, Wikoff D. 2012. US EPA’s proposed toxicity values for TCDD: Implications for decision-making regarding the safety of foods in the United States. Presented at the Society of Toxicology’s 51st Annual Meeting, March 11-15, San Francisco, CA.

Thompson CM, Fedorov Y, Brown DD, Suh M, Proctor DM, Kuriakose L, Haws L, Harris MA. 2012. Assessment of Cr(VI)-induced cytotoxicity and genotoxicity using high content analysis. PLoS ONE 7(8): e42720.

Hays SM, Kirman C, Aylward L, Suh M, Proctor D. 2012. Gastric reduction of Cr(VI) in mice, rats and humans. Presented at the Society of Toxicology’s 51st Annual Meeting, March 11-15, San Francisco, CA.

Thompson CM, Hixon JG, Proctor DM, Haws LC, Suh M, Urban JD, Harris MA. 2012. Assessment of genotoxic potential of Cr(VI) in the mouse duodenum: An in silico comparison with mutagenic and nonmutagenic carcinogens across tissues. Regul Toxicol Pharmacol 64(1): 68-76.

Hixon JG, Proctor D. 2012. Use of constrained logistic regression models for the dose-response analysis of beryllium sensitization and chronic beryllium disease with mean exposure. Presented at the Society of Toxicology’s 51st Annual Meeting, March 11-15, San Francisco, CA.

Thompson CM, Proctor DM, Suh M, Haws LC, Hebert CD, Mann JF, Shertzer HG, Hixon JG, Harris MA. 2012. Comparison of the effects of hexavalent chromium in the alimentary canal of F344 rats and B6C3F1 mice following exposure in drinking water: Implications for carcinogenic modes of action. Toxicol Sci 125(1):79-90.

Kim S, Kopec A, Forgacs AL, Thompson CM, Zacharewski T. 2012. Genome-wide gene expression analysis of Cr(VI) effects in Fisher rat small intestinal epithelium. Presented at the Society of Toxicology’s 51st Annual Meeting, March 11-15, San Francisco, CA.

Thompson CM, Proctor DM, Harris MA. 2012. Duodenal GSH/GSSG ratios in mice following oral exposure to Cr(VI). Toxicol Sci 126(1):287-288.

Kirman CR, Hays SM, Aylward LL, Suh M, Proctor D. 2012. Physiologically-based pharmacokinetic model for mice, rats and humans orally-exposed to chromium. Presented at the Society of Toxicology’s 51st Annual Meeting, March 11-15, San Francisco, CA.

Giovinazzo H, Kumar P, Sheikh A, Ivanovic M, Walsh MD, Caron WP, Song G, Whitlow AB, Newman SE, La-Beck N, Kowalsky RJ, Zamboni BA, Clarke-Pearson DL, Brewster WR, Le LV, Bae-Jump VL, Gehrig PA, Zamboni WC. Technetium-99m sulfur colloid as a phenotypic probe for predicting pharmacokinetics and parlmar-plantar erythrodysesthesia toxicity of PEGylated liposomal doxorubicin in patients with recurrent epithelial ovarian cancer. J Clin Oncol 30 (suppl) [abstract 5050]. Presented at the American Society of Clinical Oncology Annual Meeting, Chicago, IL, June 2012.

Song G, Tarrant TK, Barrow DA, Gehrig PA, Hanna SK, Strychor S, Ramalingam S, Belani CP, Edwards RP, Ramanathan RK, Zamboni WC. The effect of CC Chemokine ligand-2 (CCL2/MCP-1) and CC Chemokine ligand-6 (CCL5/RANTES) on the pharmacokinetics and the pharmacodynamics of PEGylated liposomal CKD602 (S-CKD602) in patients with advanced solid tumors. Cancer Research 72(8):754 [abstract 754]. Presented at the American Association of Cancer Research Annual Meeting, Chicago IL, April 2, 2012.

Song G, Moore SM, Tarrant TK, Dobrovolskaia MA, Barrow DA, Kumar P, Newman SE, Bae-Jump VL, Gehrig PA, Zamboni WC. Relationship between complement factors and CC chemokines and the pharmacokinetics and pharmacodynamics of PEGylated liposomal doxorubicin in patients with refractory epithelial ovarian cancer [abstract 126]. Presented at 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Dublin, Ireland, November 8, 2012.

Song G, Wu H, Yoshino K, Zamboni WC. 2012. Factors affecting the pharmacokinetics and pharmacodynamics of liposomal drugs. J Liposome Res 22(3):177–192.

Caron WP, Song G, Kumar P, Rawal S, Zamboni WC. 2012. Interpatient pharmacokinetic and pharmacodynamics variability of carrier-mediated anticancer agents in patients. Clin Pharmacol Ther
91(5):802–812.

Berman DW, Brorby GP, Sheehan PJ, Bogen KT, Holm SE. 2012. More on the dynamics of dust generation: The effects of mixing and sanding chrysotile, calcium carbonate, and other compounds on the characteristics of joint-compound dusts. Ann Occup Hyg 56(7):852-867.

Kopec A, Forgacs AL, Kim S, Thompson CM, Zacharewski T. 2012. Comparative toxicogenomic analysis of Cr(VI) effects in rat and mouse small intestine. Presented at the Society of Toxicology’s 51st Annual Meeting, March 11-15, San Francisco, CA.

Fowler, JC, Bhattacharya S, Urban JD, Vaidehi N, Mailman RB. 2012. Receptor conformations involved in dopamine D2L receptor functional selectivity induced by selected transmembrane 5 serine mutations. Mol Pharmacol 81(6):820-831.

Mounho B. 2012. Overview of the history and development of regional guidelines for the approval of biosimilar products. Presented at the Society of Toxicology’s 51st Annual Meeting, March 11-15, San Francisco, CA.

Henderson RG, Durando J, Oller A, Merkel DJ, Marone PA,  Bates HK. 2012. Acute oral toxicity of nickel compounds. Regul Toxicol Pharmacol 62(3):425-432.

O’Brien TJ, Hao D, Suh M, Proctor D, Thompson CM, Harris MA, Parsons BL, Meyers MB. 2012. K-ras codon 12 GGT to GAT mutation is not elevated in the duodenum of mice subchronically exposed to hexavalent chromium in drinking water. Presented at the Society of Toxicology’s 51st Annual Meeting, March 11-15, San Francisco, CA.

Henderson RG, Cappellini D, Seilkop SK, Bates HK, Oller AR. 2012. Oral bioaccessibility testing and read-across hazard assessment of nickel compounds. Regul Toxicol Pharmacol 63(1):20-28.

Perry C, Tachovsky JA, Ke M, Urban J, Haws L. 2012. Natural gas exploration and production in the Barnett Shale: Assessment of exposures to volatile organic compounds (VOCs). Presented at the Society of Toxicology’s 51st Annual Meeting, March 11-15, San Francisco, CA.

Urban J, Budinsky R, Rowlands J. 2012. An evaluation of single nucleotide polymorphisms in the human heat shock protein 90kDa alpha and beta isoforms. Drug Metab Pharmacokinet 27(2):268-278.

Proctor DM, Thompson CM, Suh M, Haws LC, Harris MA. 2012. Mode of action for intestinal carcinogenesis of ingested hexavalent chromium in mice. Presented at the Society of Toxicology’s 51st Annual Meeting, March 11-15, San Francisco, CA.

Thompson CM, Hixon JG, Kopec AK, Harris MA, Proctor DM, Haws LC. 2012. Assessment of genotoxic potential of Cr(VI) in the mouse duodenum via toxicogenomic profiling. Presented at the Society of Toxicology’s 51st Annual Meeting, March 11-15, San Francisco, CA.

Urban J, Rowlands JC, Budinsky R, Dombkowski A, Thompson CM, Thomas RS. 2012. A genomics-based benchmark dose analyses of relative potencies of dioxin-like compounds in primary rat hepatocytes. Presented at the Society of Toxicology’s 51st Annual Meeting, March 11-15, San Francisco, CA.

Wikoff D, DeVito M, Walker N, Hixon G, Harris M, Tachovsky A, Birnbaum L, Haws L. 2012. Application of machine learning in the development of a weighting framework for evaluating eEstimates of relative potency for dioxin-like compounds. Presented at the Society of Toxicology’s 51st Annual Meeting, March 11-15, San Francisco, CA.

Mounho B. 2012. Regulatory standards for the approval of biosimilar products: A global review. Presented in Münster, Germany, May 23.

Mounho B. 2012. History and review of regulatory pathways for the approval of biosimilar products. Presented at Applied Pharmaceutical Toxicology Annual Meeting, May 17, Baltimore, MD.